Table 1 Demographic, clinical characteristics and NGS-based treatment (n = 218)
Age at diagnosis | |
Mean (range) – years | 65.5 (28–85) |
Sex – no. (%) | |
Male | 163 (74.8) |
Female | 55 (25.2) |
Race – no. (%) | |
White | 172 (78.9) |
Black | 20 (9.2) |
Asian | 6 (2.8) |
American Indian/Alaska Native | 0 |
Other | 0 |
Unknown | 20 (9.2) |
ECOG PS – no. (%) | |
0 | 87 (39.9) |
1 | 96 (44.0) |
2 | 28 (12.8) |
3 | 7 (3.2) |
Smoking status – no. (%) | |
Current | 18 (8.3) |
Former | 130 (59.6) |
Never | 69 (31.7) |
Unknown | 1 (0.5) |
Tumor origin at initial diagnosis - no. (%) | |
Bladder | 182 (83.5) |
Ureter | 12 (5.5) |
Renal pelvis | 11 (5.0) |
Urethra | 1 (0.5) |
>1 site | 12 (5.5) |
Primary surgery – no. (%) | |
Radical cystectomy | 104 (47.7) |
TURBT only | 52 (23.9) |
Radical nephroureterectomy | 25 (11.5) |
Other | 10 (4.6) |
No primary surgery | 27 (12.4) |
Time from initial diagnosisa to metastatic disease | |
Median (range) – years | 0.8 (0.0–9.8) |
Systemic therapy – no. (%) | |
Perioperative chemotherapy | 100 (45.9) |
Neoadjuvant | 73 (33.5) |
Adjuvant | 31 (14.2) |
Any systemic therapy for metastatic disease | 187 (85.8) |
Chemotherapy | 107 (49.1) |
Immunotherapy | 159 (72.9) |
Targeted therapy | 15 (6.9) |
Antibody-drug conjugate therapy | 26 (11.9) |
Unknown | 4 (1.8) |
Survivalb - no. (%) | |
Alive | 91 (41.7) |
Dead | 127 (58.3) |
Cause of death – no. (%) | |
Disease-related | 114 (89.8) |
Treatment-related | 4 (3.2) |
Other | 6 (4.7) |
Unknown | 3 (2.4) |
NGS-based treatment decisions – no. (%) | |
NGS provided treatment options | |
Yes | 151 (69.3) |
No | 63 (28.9) |
No response | 4 (1.8) |
Any targeted therapy received per NGS | 11 (5.0) |
Targeted therapy on clinical trial per NGS | 7 (3.2) |
